Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lymphoma
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
By
Wayne Kuznar
Immunotherapy
,
Leukemia
,
Lymphoma
,
Hematologic Malignancies
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Many patients with leukemia or lymphoma who receive treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieve minimum residual disease (MRD) negativity, and many are in complete remission well beyond 12 months.
Read Article
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
By
Charles Bankhead
Lymphoma
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Patients with relapsed, refractory, or high-risk hematologic malignancies obtained durable benefits with the combined checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) as consolidation therapy after stem-cell transplant, according to results of a small prospective study presented at ASH 2018.
Read Article
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
By
Wayne Kuznar
Lymphoma
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Zanubrutinib, a highly specific and irreversible next-generation Bruton’s tyrosine kinase (BTK) inhibitor, exhibited excellent activity in a single-arm, open-label multicenter phase 2 clinical trial of patients with relapsed or refractory mantle-cell lymphoma (MCL). Early study results were reported at ASH 2018.
Read Article
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
By
Loretta Fala
FDA Approvals, News & Updates
,
Hematologic Malignancies
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Diffuse large B-cell lymphoma (DLBCL), a form of cancer that starts in the lymphatic system, is the most common type of non-Hodgkin lymphoma (NHL) in adults. In the United States, approximately 72,000 new cases of NHL are diagnosed annually; more than 20,000 people were estimated to die from the disease in 2017.
Read Article
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Marginal-zone lymphoma (MZL) arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. MZL is divided into 3 subtypes, including mucosa-associated lymphoid tissue (MALT), nodal MZL, and splenic MZL. MALT lymphoma is the most common of these subtypes and occurs in the stomach, intestines, salivary glands, thyroid, eyes, and lungs. In MALT lymphoma, autoimmune processes or chronic infection cause B-cells to accumulate.
Helicobacter pylori
is 1 of at least 6 microbial species associated with lymphoproliferation in gastric MALT lymphoma.
Read Article
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma (NHL), comprising approximately ≥4% of NHL cases in the United States. Mantle-cell lymphoma most often affects men aged ≥60 years, and the key factors affecting prognosis include the patient’s age, performance status, lactate dehydrogenase levels, and white blood cell count.
Read Article
PET-Directed Approach Can Guide Radiation Therapy in Diffuse Large B-Cell Lymphoma
By
Phoebe Starr
Lymphoma
,
Solid Tumors
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A positron emission tomography (PET)-directed approach after standard chemotherapy can guide the need for consolidation radiation therapy in patients with diffuse large B-cell lymphoma (DLBCL). This approach can spare patients from further treatments, such as salvage chemotherapy and stem-cell transplant, as well as unnecessary radiation therapy, according to a study presented at ASH 2017.
Read Article
Brentuximab Vedotin plus Nivolumab Yields High Complete Responses in Relapsed or Refractory Hodgkin Lymphoma
By
Chase Doyle
Lymphoma
,
Solid Tumors
,
Personalized Medicine
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Interim results from a phase 1/2 study of the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) have demonstrated a high overall response rate (ORR) in patients with relapsed or refractory Hodgkin lymphoma. According to data presented at ASH 2017, 83% of patients responded to the combination, which included a 62% rate among efficacy-evaluable patients.
Read Article
High Response Rate with 3-Drug Combination for Untreated Follicular Lymphoma
By
Charles Bankhead
Lymphoma
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Among patients with untreated follicular lymphoma, 75% achieved complete responses with the 3-drug combination of atezolizumab (Tecentriq), obinutuzumab (Gazyva), and bendamustine (Treanda), results of a small, preliminary clinical trial reported at ASH 2017 showed.
Read Article
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
By
Phoebe Starr
Lymphoma
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—Adding brentuximab vedotin (Adcetris) to doxorubicin, vinblastine, and dacarbazine (A+AVD) instead of the standard regimen with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline treatment for advanced Hodgkin lymphoma reduced the risk for disease progression, death, or the need for additional therapy by 23%, according to new data presented at ASH 2017.
Read Article
Page 4 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma